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Abstract
Aims/hypothesis In an individual-level analysis we examined
the effect of atorvastatin on glycaemia progression in type 2
diabetes and whether glycaemia effects reduce the prevention
of cardiovascular disease (CVD) with atorvastatin.
Methods The study population comprised 2,739 people tak-
ing part in the Collaborative Atorvastatin Diabetes Study
(CARDS) who were randomised to receive atorvastatin
10 mg or placebo and who had post-randomisation HbA1c
data. This secondary analysis used Cox regression to estimate
the effect of atorvastatin on glycaemia progression, defined as
an increase in HbA1c of ≥0.5% (5.5 mmol/mol) or inten-
sification of diabetes therapy. Mixed models were used
to estimate the effect of atorvastatin on HbA1c as a con-
tinuous endpoint.
Results Glycaemia progression occurred in 73.6% of partici-
pants allocated placebo and 78.1% of those allocated atorva-
statin (HR 1.18 [95% CI 1.08, 1.29], p<0.001) by the end of
follow-up. The HR was 1.22 (95% CI 1.19, 1.35) in men and
1.11 (95% CI 0.95, 1.29) in women (p=0.098 for the sex
interaction). A similar effect was seen in on-treatment analy-
ses: HR 1.20 (95% CI 1.07, 1.35), p=0.001. The net mean
treatment effect on HbA1c was 0.14% (95% CI 0.08, 0.21)
(1.5 mmol/mol). The effect did not increase through time. Di-
abetes treatment intensification alone did not differ with statin
allocation. Neither baseline nor 1-year-attained HbA1c predict-
ed subsequent CVD, and the atorvastatin effect on CVD did
not vary by HbA1c change (interaction p value 0.229).
Conclusions/interpretation The effect of atorvastatin 10 mg
on glycaemia progression among those with diabetes is statis-
tically significant but very small, is not significantly different
between sexes, does not increase with duration of statin and
does not have an impact on the magnitude of CVD risk reduc-
tion with atorvastatin.
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Introduction
Although there is unequivocal evidence for the efficacy of
statins in the prevention of cardiovascular disease (CVD),
there continues to be intense debate about the adverse effects
of statin therapy. There are concerns both about over-
prescribing and conversely that patients warranting treatment
are being deterred from treatment by inaccurate reports on
adverse events [1, 2]. One potential adverse effect is an in-
creased risk of diabetes. This increased risk was reported in
Justification for the Use of Statins in Primary Prevention: an
Intervention Trial Evaluating Rosuvastatin (JUPITER), a trial
of rosuvastatin in people with elevated C-reactive protein, in
which 3% of statin-treated and 2.4% of placebo-arm partici-
pants developed diabetes [3]. Subsequent meta-analyses of
statin trials reported increased risks [4, 5] and observational
studies also reported increased risks [6]. In 2012 the US Food
and Drug Administration required that the drug safety label
was amended to indicate an increased risk [7]. However, the
aforementioned meta-analyses were not able to directly quan-
tify the effect of statins on plasma glucose or on HbA1c as
these variables were not regularly measured in the trials
examined. A recent study from Finland reported an even
higher 46% increase in diabetes incidence associated with
statins [8] accompanied by both loss of insulin sensitivity
and secretion. However this observational study could be sub-
ject to substantial confounding by indication.
These data have also raised concerns about potential ad-
verse effects on diabetes in those who already have diabetes at
the start of statin therapy. Recently, a combined analysis of
published treatment-arm summary data on HbA1c from statin
trials concluded that there was a small average effect on
HbA1c among those with diabetes [9]. However, this meta-
analysis relied simply on published treatment-arm mean
values at arbitrary points of follow-up and, as acknowledged
by the authors, could not consider changes in diabetes drug
use during follow-up. Thus, the estimates it used could be
inaccurate and subject to competing risks bias. Furthermore,
important questions remain about whether effects increase
through duration of exposure. It is also unclear whether the
reported effects on glycaemia reflect large effects occurring
rarely in some susceptible subgroup of patients or small ef-
fects occurring commonly. Little is known about how any
glycaemia effect relates to the degree of LDL-cholesterol
(LDL-c) lowering or to other drug effects including liver func-
tion test changes. To address these questions individual-level
data rather than meta-analyses are required.
Here we used individual-level data from a large primary
prevention trial of atorvastatin 10 mg in people with existing
diabetes at entry to directly test the effect of this statin on
glycaemia progression as indexed by intensification of
diabetes drug treatment or increasing HbA1c. We used a com-
peting risks method that takes account of reduced CVD rates
in those on statin therapy. We examined whether effects in-
creased with duration of statin use and whether effects differed
by sex. To explain possible mechanisms, we tested whether
any effects were likelymediated by increased BMI and wheth-
er they related to the degree of LDL-c lowering or changes in
liver function tests on treatment with statin. Finally we tested
whether any adverse effect on glycaemia had an impact on the
CVD risk reduction achieved with atorvastatin. Our analysis
allows greater insight into the likely causality andmechanisms
underlying any association and provides a practical insight
allowing people with diabetes to weigh the benefits and risks
of statin therapy given their condition.
Methods
Study population The Collaborative Atorvastatin Diabetes
Study (CARDS; ClinicalTrial.gov registration no.
NCT00327418) has been described in detail previously [10].
In brief, CARDS was a multicentre, randomised, placebo-
controlled trial in 2,838 patients with type 2 diabetes aged
40–75 years carried out in 132 centres in the UK and Ireland.
Patients were randomised to receive either placebo (n=1,410)
or atorvastatin 10 mg (n=1,428) daily. Study entrants had no
documented previous history of CVD, an LDL-c concentra-
tion of 4.14 mmol/l or lower, a fasting triacylglycerol level of
6.78 mmol/l or less and an HbA1c<12% (<108 mmol/mol).
The primary endpoint was time to first occurrence of acute
coronary heart disease events, coronary revascularisation or
stroke. The study was carried out in accordance with the Dec-
laration of Helsinki and the guidelines on Good Clinical Prac-
tice, with each centre obtaining Local Research Ethics Com-
mittee approval following approval from the Multi-centre Re-
search Ethics Committee. All patients gave fully informed
written consent. Type 2 diabetes was defined using the 1985
WHO criteria [11]. The analysis population for this study
consisted of 2,739 patients with at least one post-
randomisation HbA1c reading. This is a secondary analysis
but before conducting this analysis all outcome measures
and the analytical approach were pre-specified.
Outcome measurement We pre-specified a composite end-
point for glycaemia progression defined as an absolute in-
crease in HbA1c of at least 0.5% (5.5 mmol/mol) and/or an
increase in the intensity of anti-glycaemic drug therapy. Inten-
sity was defined by an ordinal variable set: 0 for neither oral
drugs nor insulin; 1 for only one oral drug; 2 for two oral
drugs; 3 for three or more oral drugs and 4 for insulin (regard-
less of the number of oral drugs). Non-insulin anti-glycaemic
drugs observed in this study consisted mainly of metformin
and sulfonylureas; the rare use ofα-glucosidase inhibitors and
the negligible use of thiazolidinediones and aldose reductase
inhibitors was consistent with the era in which the study was
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conducted. The secondary pre-specified analysis was of
HbA1c change examined as a continuous variable.
HbA1c was recorded at randomisation and then annually.
We measured HbA1c in whole blood containing fluoride oxa-
late using a Biorad Diamat high-pressure liquid chromatogra-
phy analyser (Biorad, Hercules, CA, USA), with standards
and controls supplied by the manufacturer. The upper limit
of normal for the laboratory was 6.5% (48 mmol/mol). Aspar-
tate aminotransferase (AST) or alanine aminotransferase
(ALT) were measured using a Hitachi 747 autoanalyser,
(Hitachi, Tokyo, Japan), with standards and controls recom-
mended by the manufacturer. Serum cholesterol and triacyl-
glycerol concentrations were measured by an automated en-
zymatic method. In samples not requiring ultracentrifugation
(i.e. serum triacylglycerol ≤4 mmol/l) heparin-manganese
precipitation of apo-B-containing lipoproteins was carried
out on whole serum and HDL-cholesterol remaining in the
supernatant fraction was measured by an enzymatic method.
The LDL-c was then calculated using the Friedewald formula.
BMI (kg/m2) was measured at baseline and at every visit
thereafter. Waist–hip ratio was only captured at baseline. Con-
current medications were recorded at every visit.
Statistical methods Analyses were by intention-to-treat unless
stated otherwise. All available data from randomisation were
used, right censoring at the earliest of death, close-out date or
last follow-up for cardiovascular morbidity. When we examined
the effect of atorvastatin on glycaemic control the data were
further right censored at the earlier of the last available HbA1c
measurement or loss to follow-up for concomitant medication.
On-treatment, sensitivity analyses were further right censored
after the date of first withdrawal from the study drug.
Cox regression models were fitted to the time to the binary
outcome of glycaemia progression, stratified by major CVD
status and adjusted for baseline age and diabetes duration with
further adjustment for baseline lipids. Models were either ad-
justed for, or stratified by, sex. Effects on glycaemia progres-
sion were also analysed considering major CVD or death as
competing risks using the method of Fine and Gray [12]. To
test whether any effects of glycaemia progression were more
pronounced with certain characteristics we tested for an inter-
action between the treatment effect on glycaemia progression
and the characteristic concerned. To establish whether any
treatment-associated progression was directly related to lipid
lowering or possibly to other adverse effects, within-person
changes in LDL-c and in AST, ALT, their ratio and serum
creatinine kinase from randomisation to 6 months post-
randomisation were calculated. The atorvastatin patients were
dichotomised according to whether or not they showed a
change over 6 months within the top tertile of change in
LDL-c, AST, ALT as appropriate; each atorvastatin group
was compared with all placebo patients in terms of subsequent
glycaemia progression.
Maximum likelihood estimation was used to fit (repeated
measures) linear mixed models to longitudinal data on HbA1c
andBMI using an unstructured covariance structure and nesting
observations within patients and patients within trial sites. All
models were adjusted by baseline age and diabetes duration and
by linear and quadratic terms for time since randomisation.
Models were fitted separately by sex, and for HbA1c a model
was also fitted to data on both sexes combined adjusting for sex.
Models of HbA1c change were further adjusted by baseline
values of other baseline characteristics, and time-updated vari-
ables for BMI, anti-glycaemic drug intensity and having had a
major CVD event. The effects of study drug onHbA1c andBMI
at 1 year post-randomisation were also assessed by simple
ANCOVAmodels since at this time point there was less poten-
tial (compared with the full follow-up period) for interference
by other factors such as changing diabetes drug therapy.
To understand the impact of these HbA1c changes on CVD
risk we first examined whether baseline or time-updated
HbA1c predicted CVD events Cox regressionmodels.We then
used tests for interaction to examine the effect of atorvastatin
on CVD in patients with an above-median vs below-median
change in HbA1c at year 1. In these models, the entry time was
the end of year 1 and those with a first CVD event in that first
year were excluded.
All analyses were conducted using Stata/MP 11.1, StataCorp,
College Station, TX, USA. Conventional p value thresholds of
0.05 were used for declaring statistical significance.
Results
Of 2,838 randomised patients, 2,739 (96.5%) had at least one
follow-up HbA1c reading. The baseline characteristics of the
analysis population were very similar by treatment arm, as
shown in electronic supplementary material (ESM) Table 1.
Themean baseline HbA1c was slightly higher in the atorvastatin
arm, by 0.05% (0.6mmol/mol). Themean follow-up for HbA1c
change in the placebo group and atorvastatin group was 3.2 and
3.3 years, respectively; 95.3% of the participants had at least
two readings and 76.0% and 47.4% had at least three or four
follow-up readings, respectively. After censoring for loss to
follow-up for concurrent medication or cardiovascular morbid-
ity, the analysis population was reduced to 2,721 patients.
Time-to-event analyses of glycaemia progressionBy end of
follow-up, glycaemia progression occurred in 996 of 1353
placebo patients (73.6%) and 1,069 of 1368 of atorvastatin
patients (78.1%) (see Table 1 for sex-specific data). Adjusting
for sex, baseline age, diabetes duration and HbA1c, and strat-
ifying by major CVD status, the HR for the treatment effect
was 1.18 (95% CI 1.08, 1.29) p<0.001 in both sexes com-
bined. Glycaemia progression occurred in 78.7% of men allo-
cated atorvastatin and 73.3% allocated placebo (HR 1.22
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[95% CI 1.10, 1.35], p<0.001). Progression occurred in
77.0% and 74.4% of women allocated atorvastatin or placebo,
respectively (HR 1.10 [95% CI 0.95, 1.29], p=0.197;
p=0.289 for the diabetes by sex interaction).
These findings were robust to further adjustment by the
baseline lipid levels and intensity of diabetes therapy at base-
line. In the competing risk analysis the sub-hazard of
glycaemia progression was similar to the main model at HR
1.21 (95% CI 1.11, 1.32), p<0.001. In a sensitivity analysis
redefining progression as intensification of diabetes therapy or
at least two consecutive HbA1c readings at least 0.5%
(5.5 mmol/mol) greater than baseline, a similar HR was ob-
served (HR 1.18 [95% CI 1.07, 1.30], p=0.001).
Overall glycaemia progression during follow-up was posi-
tively associated with younger age and lower baseline HbA1c,
lower HDL-c concentration (p=0.003) and higher triacylglyc-
erol level (p=0.002) but was not associated with LDL-c con-
centration (p=0.720) or diabetes duration. However, there was
no evidence that these or any other characteristics, including
metabolic syndrome (p=0.243) as previously defined, height-
ened the effect of atorvastatin on progression [13]. We found
no evidence that the effect on glycaemia progression varied by
tertile of post-treatment change in LDL-c (likelihood ratio test
p value=0.164), creatinine kinase (p=0.241) or AST
(p=0.209) but found evidence that it did vary by change in
ALT. Those in the top tertile for change from baseline in ALT
had an HR of 1.39 (95% CI 1.19, 1.62) for the atorvastatin
effect on glycaemia progression compared with an HR of 1.14
(95%CI 1.00, 1.62) for glycaemia progression associatedwith
atorvastatin for those in the bottom tertiles for ALT change
(p=0.023 for the difference in treatment effect). This interac-
tion was also present using the ALT:AST ratio.
See Table 1 and ESM Table 2 for a summary and details,
respectively, of change in intensity of diabetes therapy from
baseline. Overall there was no significant difference between
treatment arms in the percentage of patients who progressed
by at least one category of drug intensity with an HR of 1.09
(95% CI 0.96, 1.24), p=0.184. Thus, most of the observed
effect on glycaemia progression was ascertained through an
effect on HbA1c; subsequent analyses focused on that but also
adjusted for time-dependent changes in diabetes drug
intensity.
Effects on HbA1c as a continuous traitHbA1c increase by at
least 0.5% (5.5 mmol/mol) from baseline by treatment arm is
shown in Table 1, and Table 2 shows median baseline and last
follow-up level of HbA1c and within-person changes from
baseline over time by treatment arm. Overall the majority of
participants in both treatment arms experienced such a rise at
some point during follow-up (Table 1). However these in-
creases were not always sustained and there was considerable
fluctuation. Thus, using all available follow-up readings for
HbA1c in the mixed model, the median within-person change
was much lower than 0.5% (5.5 mmol/mol) and the observed
treatment effect, as detailed in Table 3, was 0.14 (95%CI 0.08,
0.21)% (1.5 [95% CI 0.8, 2.3] mmol/mol). Further adjustment
(Models 2 and 3 in Table 3) for baseline lipids blood pressure,
waist–hip ratio, baseline and time-updated BMI, diabetes drug
intensity and time-updated CVD did not alter these findings.
As shown, the difference between treatment arms was
Table 1 Cumulative incidence from baseline of increase in HbA1c of ≥0.5% (5.5 mmol/mol) or intensification of anti-glycaemic drug
therapy, or both, by treatment group
Time from baseline Absolute increase in HbA1c of ≥0.5% Intensification of anti-glycaemic drug therapy Composite of either endpoint
Placebo Atorvastatin Placebo Atorvastatin Placebo Atorvastatin
Men
1 year 38.0 (1.6), 873 47.7 (1.7), 887 0.8 (0.3), 873 1.6 (0.4), 887 38.8 (1.7), 873 48.9 (1.7), 887
2 years 55.7 (1.7), 844 61.0 (1.7), 854 7.1 (0.9), 844 6.6 (0.8), 854 60.1 (1.7), 844 64.4 (1.6), 854
3 years 65.7 (1.8), 665 70.2 (1.8), 681 14.3 (1.3), 665 14.4 (1.3), 681 69.5 (1.8), 665 74.9 (1.7), 681
4 years 69.8 (2.3), 404 76.0 (2.1), 417 31.4 (2.2), 404 33.9 (2.2), 417 78.7 (2.0), 404 84.2 (1.8), 417
Last follow-up 61.9 (1.6), 916 68.3 (1.5), 929 34.2 (1.5), 916 34.5 (1.5), 929 73.3 (1.5), 916 78.7 (1.3), 929
Women
1 year 43.6 (2.5), 408 45.3 (2.4), 417 0.5 (0.3), 408 2.2 (0.7), 417 43.9 (2.5), 408 46.5 (2.4), 417
2 years 58.5 (2.5), 402 61.1 (2.4), 404 4.7 (1.1), 402 6.2 (1.2), 404 60.0 (2.4), 402 63.4 (2.4), 404
3 years 68.0 (2.7), 300 70.8 (2.6), 318 14.0 (2.0), 300 14.5 (2.0), 318 72.7 (2.0), 300 75.5 (2.4), 318
4 years 73.7 (3.2), 186 77.1 (2.9), 205 26.3 (3.2), 186 32.2 (3.3), 205 80.1 (2.9), 186 86.3 (2.4), 205
Last follow-up 66.4 (2.3), 437 67.0 (2.2), 439 28.8 (2.2), 437 37.1 (2.3), 439 74.4 (2.1), 437 77.0 (2.0), 439
Data are shown as cumulative incidence, % (SE), denominator
Data are based on 2,721 patients with 9,146 HbA1c observations after right censoring for loss to follow-up for medications and cardiovascular morbidity
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apparent at the median within-person changes. Thus, the treat-
ment effect was consistent with a subtle shift in the change
across the distribution rather than a large treatment effect oc-
curring in a small set of patients.
We also examined the net change at 1 year (during which
time there was little change in intensity of drug treatment) and
found similar effects. As shown in Fig. 1, the change in HbA1c
occurred mostly in the first year, with both placebo and atorva-
statin groups showing increases and with no apparent worsen-
ing of the difference between the treatment arms through time.
On-treatment sensitivity analyses On-treatment analyses
showed the same pattern as intent to treat. For glycaemia pro-
gression, the effect size was HR 1.20 (95% CI 1.07, 1.35),
p=0.001 (HR 1.25 [95% CI 1.09, 1.44], p=0.002 in men and
HR 1.13 [95% CI 0.92, 1.38], p=0.240 in women; treatment–
sex interaction p value=0.332). For the effect on HbA1c the
effect size was HR 0.17 (95% CI 0.10, 0.25)% (HR 2.6 [95%
CI 1.5, 3.6] mmol/mol), p<0.001, being HR 0.23 (95% CI
0.14, 0.33)% (HR 1.9 [95% CI 1.1, 2.8] mmol/mol),
p<0.001, in men and HR 0.07 (−0.07,0.22)% (HR 0.8 [95%
CI −0.8, 2.4] mmol/mol), p=0.310, in women.
Treatment effect onBMI There was no evidence for an effect
of atorvastatin on BMI (β coefficient 0.02 [95% CI −0.06,
0.10], p=0.591). Including time-updated BMI as well as base-
line BMI values in the analysis of treatment effect on HbA1c
did not explain any of the variation in HbA1c change.
Impact of HbA1c change with treatment on the effect of
atorvastatin on CVD Baseline HbA1c did not predict major
CVD (HR per percentage unit adjusted for age and sex 1.08
[95% CI 0.98, 1.19], p=0.110). Nor did HbA1c attained at
1 year predict subsequent major CVD (HR 1.08 [95% CI
Table 2 Median HbA1c levels at baseline and within-person change from baseline to end of follow-up by treatment arm
Variable Men Women Men and women
Placebo
(n=924)
Atorvastatin
(n=937)
Placebo
(n=437)
Atorvastatin
(n=441)
Placebo
(n=1,361)
Atorvastatin
(n=1,378)
Baseline HbA1c, % 7.6 (6.8–8.7) 7.7 (6.8–8.7) 7.6 (6.9-8.8) 7.8 (6.9–8.9) 7.6 (6.8–8.7) 7.8 (6.8–8.7)
Baseline HbA1c, mmol/mol 59.6 (50.8–71.6) 60.7 (50.8–71.6) 59.6 (51.9-72.7) 61.7 (51.9–73.8) 59.6 (50.8–71.6) 61.7 (50.8–71.6)
Last follow-up HbA1c, % 7.8 (7.0–8.7) 7.9 (7.1–9.0) 7.8 (7.1-8.9) 8.0 (7.1–8.9) 7.8 (7.1–8.8) 7.9 (7.1–9.0)
Last follow-up HbA1c, mmol/mol 61.7 (53.0–71.6) 62.8 (54.1–74.9) 61.7 (54.1-73.8) 63.9 (54.1–73.8) 61.7 (54.1–72.7) 62.8 (54.1–74.9)
Unadjusted within-person change
in HbA1c, %
0.2 (−0.5–0.9) 0.3 (−0.5–1.1) 0.3 (-0.6-1.1) 0.2 (−0.6–1.0) 0.2 (−0.5–1.0) 0.2 (−0.5–1.1)
Unadjusted within-person change
in HbA1c, mmol/mol
2.2 (−5.5–9.8) 3.3 (−5.5–12.0) 3.3 (-6.6-12.0) 2.2 (−6.6–10.9) 2.2 (−5.5–10.9) 2.2 (−5.5–12.0)
Data are median (IQR), unless otherwise stated
Table 3 Mixed model estimate of the effect of atorvastatin on change in HbA1c using all available follow-up HbA1c measures
Model Net treatment effect
Men (n=1,861) Women (n=878) Men and women (n=2,739)
Model 1a
% 0.18 (0.11, 0.26) 0.06 (−0.06, 0.18) 0.14 (0.08, 0.21)
mmol/mol 2.0 (1.2, 2.9) 0.6 (−0.7, 1.9) 1.5 (0.8, 2.3
Model 2 b
% 0.18 (0.10, 0.26) 0.06 (−0.06, 0.18) 0.14 (0.07, 0.21)
mmol/mol 2.0 (1.1, 2.9) 0.7 (−0.6, 2.0) 1.5 (0.8, 2.3)
Model 3 c
% 0.18 (0.10, 0.26) 0.08 (−0.04, 0.19) 0.14 (0.08, 0.21)
mmol/mol 2.0 (1.1, 2.8) 0.8 (−0.5, 2.1) 1.5 (0.8, 2.3)
Data are shown as % (95% CI) or mmol/mol (95% CI)
In the mixed models observations were nested within patient and trial site.
aModel 1 includes fixed effects of baselineHbA1c, age, diabetes duration, sex (when analysing both sexes together) and treatment group, as well as linear
and quadratic terms for study time as random effects nested within individuals
bModel 2: Model 1+intensity of anti-glycaemic drug therapy, systolic and diastolic blood pressure, total cholesterol, HDL-c and triacylglycerols
cModel 3: Model 2+baseline waist–hip ratio and BMI, time-updated BMI, anti-glycaemic drug intensity and history of major CVD
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0.96, 1.21], p=0.214). There was no evidence of an interac-
tion between treatment and change in HbA1c dichotomised
below or above the overall median change. The HR for the
effect of atorvastatin on CVDwas 0.47 (95%CI 0.29, 0.77) in
those with below-median change in HbA1c at 1 year vs 0.63
(95% CI 0.41, 0.97) in those with above-median change
(interaction p value=0.229).
Discussion
This analysis of statin effect on glycaemia within a diabetes
population finds evidence for an effect of atorvastatin 10 mg
daily on glycaemia progression. However the effect is modest,
with a net increase in HbA1c of 0.14% (1.5 mmol/mol) by the
end of follow-up. As expected there was considerable varia-
tion between patients in the net within-person change in
HbA1c over time, with the effect of atorvastatin being very
slight in relation to this variance in within-person change. This
effect of atorvastatin on glycaemia was most apparent in the
first year following initiation of therapy and, reassuringly, did
not get worse through time. The effect seems to be subtle and
to be a common effect rather than a large effect that occurs in a
particular subgroup of patients. The only correlate of the effect
was the rise in ALT during statin therapy. Importantly, we did
not find any evidence that such effects on glycaemia have any
material impact on the large preventive effect of atorvastatin
on CVD in people with diabetes. Quantification of the
glycaemic effect in diabetes is important for helping people
already with diabetes, and their doctors, to arrive at an in-
formed decision on risks and benefits of statin therapy. Of
course, when making such decisions, other issues such as
absolute risk of CVD, co-morbidities and other potential side
effects need to be taken into consideration.
The effect on glycaemia we observed is consistent with the
findings of previous meta-analyses showing increases in inci-
dent diabetes with statins [5]. With regard to effects on
measures of glycaemia there are fewer robust analyses. Small
short-term intervention studies reported increases in insulin
and plasma glucose or glycated albumin in hyperlipidaemic
patients without diabetes [14, 15]. More recently, Erquo et al
[9] combined treatment-arm means from published trials of
those with diabetes, including unadjusted group means at
4 year follow-up, which we included as a safety analysis in
the main results paper from CARDS [10]. As acknowledged
by Erquo et al, since it was not an individual-level analysis
they could not assess whether effects were robust to alterations
in diabetes drugs throughout the trials, nor could they assess
whether or not effects increased through duration of exposure.
Also, as they did not have any data on the distribution of the
statin effect it remained unclear whether these average effects
reflect subtle common effects or rarer extreme effects [9].
With regard to the mechanism of this effect, the most recent
meta-analysis of the effect of statins on incident diabetes was
accompanied by aMendelian randomisation analysis showing
that in large association studies participants with LDL-c-
lowering single-nucleotide polymorphisms in the 3-hydroxy-
methylglutaryl-CoA reductase gene (with an allele effect on
LDL-c of 0.06 mmol/l on average) had slightly higher rates of
type 2 diabetes (OR per allele 1.02 [95% CI 1.00, 1.05]).
These data were interpreted to prove a direct relationship be-
tween LDL-c lowering with statins and increased diabetes risk
[5]. In contrast we did not find any relationship with degree of
LDL-c lowering in this study. Furthermore, in that analysis
BMI at follow-up was increased with statin therapy in active
vs placebo trials but, in contrast, we found no effect of ator-
vastatin on BMI despite having detailed data on this outcome.
We did find some evidence that those with a greater increase
in ALT following treatment were more susceptible. The
METSIM (Metabolic Syndrome in Men) population-based
study did report significant increases in 2 h glucose and glu-
cose area under the receiver operating characteristic curve of
an OGTT at follow-up for men without diabetes at baseline
[8]; reduced insulin sensitivity and secretion, along with a
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Fig. 1 Mean within-person change in HbA1c over time by treatment arm
for men (a) and women (b): intention-to-treat analysis. Black diamonds,
atorvastatin patients; white squares, placebo patients; capped lines, 95%
CI. To convert values for changes in HbA1c in% into mmol/mol, multiply
by 10.929. Treatment effect in men: 0.18 (95% CI 0.11, 0.26). Treatment
effect in women: 0.06 (95% CI −0.06, 0.08)
304 Diabetologia (2016) 59:299–306
46% increased risk of incident diabetes adjusted for baseline
were also found. However, these differences could reflect con-
founding by indication in this observational analysis where
statin recipients clearly already differed substantially from
non-recipients in characteristics at baseline, before the onset
of diabetes [8].
We examined whether there are specific subgroups of
people with diabetes who are most susceptible to the
glycaemic effect of statins. However, we did not find
any characteristics that delineated particular individuals
as being susceptible to this effect. In contrast, in an anal-
ysis of atorvastatin trials in those without diabetes at
initiation of therapy, those who developed new-onset
type 2 diabetes were more likely to have hypertension
at baseline, to be taking beta blockers and to have higher
fasting glucose, BMI, white blood cell count, systolic
and diastolic blood pressure, total cholesterol/ HDL-
cholesterol ratio, triacylglycerol level, and lower HDL-
cholesterol [16]. In the JUPITER trial, the increased risk
of diabetes with statin therapy was only observed in
those with at least one diabetes risk at entry [17]. Those
with one or more major diabetes risk factors (n=11,508)
were more likely to be women. An observational analysis
from the Women’s Health Initiative reported a 1.7-fold
increase in incident diabetes in postmenopausal women
after starting statins [6]. While adjustment for confound-
ing did not reduce this risk, the potential for residual
confounding to affect such observational studies remains.
In contrast to these findings, we found no evidence that
the effect was greater in women than in men. Sex was
not associated with new-onset type 2 diabetes in an anal-
ysis of atorvastatin trials [16].
In this study we were able to examine whether the effect of
atorvastatin on glycaemia has any substantial impact on its
ability to prevent CVD and we conclude that it does not.
The HRs are of the same order of magnitude whether
glycaemia progressed or not. Our data on the relative impor-
tance is consistent with the conclusions reached by Ridker
et al [17] in their analysis of JUPITER trial data on those
without diabetes at initiation of therapy. They concluded that
the cardiovascular and mortality benefits of statin therapy
exceeded the diabetes hazard, including in participants at high
risk of developing diabetes.
A useful aspect of our analysis that has remained un-
resolved in the meta-analyses so far is the role of com-
peting risks. Previous meta-analyses were not able to
assess the potential role of competing risk effects as
individual-level data are needed for this. Here, such for-
mal competing risk analyses showed that the glycaemia
effect could not be attributed to this. Also the overall
treatment effect is mainly driven by the change occurring
in year 1. Thus, adjusting for competing risks of CVD or
death has little effect on the findings.
The limitations of this study are that only atorvastatin rather
than other statins and only one dose, 10 mg, was evaluated.
Previous meta-analyses in individuals without diabetes have
suggested that there is a dose–response effect [5, 18]. None-
theless, a dose of 10 mg is very commonly used in diabetes;
since we have shown that many patients will achieve substan-
tial LDL-c lowering with this dose our data have wide rele-
vance. Additionally, the sample size precludes precise quanti-
fication of effects within subgroups. Although in the analysis
of effects on HbA1c we did adjust for time-updated changes in
intensity of diabetes medications, based on the number of
drugs being used, we did not adjust for dose changes within
a specific category of oral drugs. However, since the estimate
of effect really did not change at all, even when adjusting for
time-updated change in diabetes drug intensity, it seems un-
likely that it would change in a major way with the more
subtle adjustment for drug dose.
Another limitation is that we did not have retinal photo-
graph data to enable us to quantify any effects on retinopathy,
which is one of the diabetes-related complications most sus-
ceptible to glycaemia.
In conclusion, although the effect of atorvastatin
10 mg on HbA1c and on glycaemia progression in pa-
tients with diabetes is statistically significant, it is very
small and it does not increase with duration of statin use
or have an impact on the substantial reduction in CVD
risk with atorvastatin.
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